Product Development Strategies, FDA Approval, Incremental Agreement, New Clinical Studies, and Other Announcements - Research

   Product Development Strategies, FDA Approval, Incremental Agreement, New
    Clinical Studies, and Other Announcements - Research Report on Amarin,
                Discovery Labs, Auxilium, Novavax, and Accuray

PR Newswire

NEW YORK, October 9, 2013

NEW YORK, October 9, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Amarin
Corporation plc (NASDAQ: AMRN), Discovery Laboratories Inc. (NASDAQ: DSCO),
Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Novavax, Inc. (NASDAQ: NVAX),
and Accuray Incorporated (NASDAQ: ARAY). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Amarin Corporation plc Research Report

On October 3, 2013, Amarin Corporation plc (Amarin) announced that the Company
received a notification from the U.S. Food and Drug Administration's (FDA) in
connection to a scheduled advisory committee meeting. According to the
Company, FDA has notified that the meeting which is scheduled to be held on
October 16, 2013 in relation with the proposed Vascepa® (icosapent ethyl)
ANCHOR indication will take place as scheduled despite the current Federal
Government lapse in appropriations. The Full Research Report on Amarin
Corporation plc - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/7cf9_AMRN]

--

Discovery Laboratories Inc. Research Report

On October 4, 2013, Discovery Laboratories Inc. (Discovery Labs) announced
that the Company has received approval from the US Food and Drug
Administration (FDA) for its updated product specifications for SURFAXIN
(lucinactant) Intratracheal Suspension. According to the Company, SURFAXIN is
the first FDA-approved synthetic, peptide-containing surfactant available for
the prevention of respiratory distress syndrome (RDS) in premature infants,
and the only approved alternative to animal-derived surfactants currently used
today. John G. Cooper, CEO of Discovery Labs commented, "SURFAXIN represents
the first milestone in our goal of transforming the treatment of RDS and is an
important medical advancement for the neonatology community and parents of
preterm infants who will soon have an effective alternative to animal-derived
surfactants for the prevention of RDS." The Company informed that it has
started manufacturing of SURFAXIN for its planned commercial introduction in
Q4 2013. The Full Research Report on Discovery Laboratories Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/2f42_DSCO]

--

Auxilium Pharmaceuticals Inc. Research Report

On September 20, 2013, Auxilium Pharmaceuticals, Inc. (Auxilium) announced an
Incremental Assumption Agreement with Morgan Stanley Senior Funding, Inc.
(MSSF), under Auxilium's existing Credit Agreement with the latter. The
Company stated that under the Incremental Agreement, Auxilium has raised an
additional $50 million from a syndicate of lenders, on terms which are
consistent with its existing $225 million senior secured credit facility. The
Company informed that it intends to use these proceeds for general corporate
purposes, including potential corporate development and licensing activities.
The Full Research Report on Auxilium Pharmaceuticals Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/86a4_AUXL]

--

Novavax, Inc. Research Report

On September 24, 2013, Novavax, Inc. (Novavax) announced that after the
successful completion of process improvement studies, the Company is
finalizing details on costs and timelines for their next round of clinical
studies with the US Department of Health and Human Services, Biomedical
Advanced Research and Development Authority (BARDA). According to the Company,
Novavax has initiated these trials for its quadrivalent seasonal influenza
vaccine candidate and its pandemic influenza vaccine candidate, both under
U.S. INDs. According to the Company, the pandemic study will include the use
of Novavax' proprietary saponin-based adjuvant Matrix-M™. Stanley C. Erck,
President and CEO said, "Novavax is committed to moving these two vaccine
candidates through to licensure. The clinical trials we have planned for 2014
are important steps in the completion of that goal. Given the shift in the
global disease focus from the H5N1 avian influenza strain to the H7N9 avian
influenza strain we have expanded our pandemic program to include H7N9." The
Full Research Report on Novavax, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/bc35_NVAX]

--

Accuray Incorporated Research Report

On October 3, 2013, Accuray Incorporated (Accuray) announced the that studies
presented at the 55th Annual American Society for Radiation Oncology (ASTRO)
Meeting in Atlanta affirms evidence of clinical and quality of life benefits
for the CyberKnife and TomoTherapy Systems. Accuray informed that at the
meeting, several indications including prostate, lung, liver, breast and head
and neck cancers were represented among the 104 oral and poster presentations,
further strengthening Accuray's position as a leader in precise, innovative
radiation oncology therapies. Joshua H. Levine, President and CEO of Accuray
said, "Data on the CyberKnife System continued to support that it is the best
option for SBRT, while data on the TomoTherapy System reinforced its ability
to treat the entire spectrum of radiation oncology patients. Perhaps most
importantly for us, the feedback shared by our clinical partners using the new
CyberKnife M6 and TomoTherapy H Series sparked several discussions among their
colleagues about how both technologies can help expand patient access to the
most precise, leading-edge radiation therapies available. We look forward to
working with our customers to continue to learn from and share their
experiences with the radiation oncology community." The Full Research Report
on Accuray Incorporated - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/36bf_ARAY]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://AnalystsCorner.com



SOURCE Analysts' Corner

Contact: Joe Thomas; +1-310-496-8071 (North America)